Drug reimportation emerges again in health debate

NewsGuard 100/100 Score

The Hill reports that Senate Majority Leader Harry Reid "has agreed to allow Sen. Byron Dorgan (D-N.D.) to bring an amendment to a vote this week that would allow the importation of cheaper prescription drugs from abroad despite the fact that it could blow up a truce between the White House, Senate Finance Committee Chairman Max Baucus (D-Mont.) and the Pharmaceutical Research and Manufacturers of America (PhRMA) on healthcare reform." Sen. Olympia Snowe (R-Maine) is among the amendment's co-sponsors. 

The Hill adds that Dorgan "could assemble a bipartisan coalition of more than 60 votes to disregard the agreement to limit PhRMA's financial exposure in exchange for its support of reform, which would risk a battle with a powerful industry that has fought healthcare reform in the past" (Young, 12/7).

CBS News: "Dorgan's amendment would allow for the re-importation of prescription drugs from Canada, a move that could save the federal government $19 billion over 10 years, according to nonpartisan analysis. .... Meanwhile, Sen. Bill Nelson (D-Fla.) is insisting the Senate consider yet another amendment that could break up the industry agreement. Nelson wants drug makers to give the government rebates on drugs sold to Medicare and Medicaid patients, thereby closing the 'doughnut hole' -- a gap in Medicare Part D coverage. The plan could cost the industry $106 billion over 10 years" (Condon, 12/7).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Top minds in multiple sclerosis to speak at CMSC 38th Annual Meeting